Bagsværd, Denmark, 22 January 2015 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity.
Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation.The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of >= 30 kg/m2(obese), or >= 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
For further information
Media: | ||
Mike Rulis | +45 3079 3573 | [email protected] |
Ken Inchausti (US) | +1 609 514 8316 | [email protected] |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | [email protected] |
Jannick Lindegaard Denholt | +45 3079 8519 | [email protected] |
Melanie Raouzeos | +45 3075 3479 | [email protected] |
Daniel Bohsen | +45 3079 6376 | [email protected] |
Frank Daniel Mersebach (US) | +1 609 235 8567 | [email protected] |
Company announcement No 4 / 2015